Navigation Links
Replidyne Discontinues Phase III Trial
Date:4/23/2008

LOUISVILLE, Colo., April 23 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that it has discontinued enrollment in a placebo-controlled Phase III clinical trial testing faropenem medoxomil (faropenem) in patients with acute exacerbation of chronic bronchitis (AECB). Replidyne took this action to conserve its cash assets and support initiatives that include pursuing strategic transactions and maintaining its research programs.

The AECB study is one in a package of four clinical trials, including two in community-acquired pneumonia and one in acute bacterial sinusitis, recommended as a way forward by the U.S. Food and Drug Administration for a new drug application submission for faropenem to treat these three adult community respiratory tract infections. Replidyne has not initiated the other three trials, and consistent with prior guidance, further faropenem development will depend on Replidyne securing a partner for the program.

"In the interest of conserving our financial position, we have made a difficult decision to discontinue enrollment in this faropenem trial," said Kenneth J. Collins, Replidyne's President and CEO. "This decision reflects our sense of urgency and the belief that in today's environment available cash assets broaden the scope of potential partnering and strategic options."

As of March 31, 2008, Replidyne had cash assets of approximately $78 million.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's most advanced product candidate, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a fir
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Replidyne Provides Strategic Update
2. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
3. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
4. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
5. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
6. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
7. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
8. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
9. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
10. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
11. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... quarterly cash dividend for the second quarter 2015 of ... cash dividend of $0.03 per share will be paid ... record as of June 12, 2015.  The ex-dividend date ...
(Date:5/21/2015)... WASHINGTON , May 21, 2015 ... following statement regarding the Medicare Part D offsets ... Century Cures initiative: "If the 21st Century ... billions from America,s premier health program – Medicare ... it may yield down the road. ...
(Date:5/21/2015)... -- Heidrick & Struggles (Nasdaq: HSII ), the premier ... and culture shaping worldwide, strengthens its ... the addition of Tim Dietlin to the ... Dietlin has extensive life sciences and professional services ... and Commercial functions to increase productivity, drive transformational change, ...
Breaking Medicine Technology:CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Heidrick Increases Healthcare and Life Sciences Expertise 2
... SAN DIEGO, December 6, 2011 Speaking ... Antibody Conference in San Diego, Dr. Klaus Schwamborn, CDO ... the discovery of therapeutic antibodies. In his ... technology and the most recent developments of immunogen design. ...
... N.J., Dec. 6, 2011   Unity Management Group, Inc. ... Metropolitan Computing Corporation (MCC) are pleased to announce the ... The contract is valued at $105,000. The ... designed for Roller Compactors. Michael Oliver, Vice President stated, ...
Cached Medicine Technology:Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference 2Unity Management Group, Inc. Receives Contract From Sun Pharmaceutical India's Largest Pharmaceutical Companies for $105,000 2Unity Management Group, Inc. Receives Contract From Sun Pharmaceutical India's Largest Pharmaceutical Companies for $105,000 3
(Date:5/23/2015)... 2015 On Wednesday, May 20, 2015, ... has been the target of a sophisticated cyberattack,” and ... company’s ongoing Information Technology (IT) security efforts in the ... The most notable attack on health insurers was reported ... nation’s second largest health insurer, revealed that they had ...
(Date:5/23/2015)... IL (PRWEB) May 23, 2015 A live ... medical equipment from hospitals, surgery centers and other medical facilities ... be sold including endoscopy, lab, radiology, surgery, anesthesia, exam and ... Wednesday, May 27 and Thursday, May 28 starting at 9:00am ... located at 1400 N. 25th Avenue, Melrose Park, IL 60160. ...
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on the ... legislature but which has not been signed to date by ... 449 with overwhelming bipartisan support on April 10, 2015, ... This bill ensures that fracking is prohibited in Maryland through ... of fracking to our water supplies and the air we ...
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... New York, New York (PRWEB) May 22, 2015 ... ( http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals ... complications due to its use continue to move ... of Louisiana. According to a Pretrial Order dated ... governing the preservation of documents and electronically stored ...
Breaking Medicine News(10 mins):Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4
... could offer new treatments for other autoimmune disorders, study ... believe they have finally answered a basic question about ... body does the wheat protein gluten enter one,s system? ... Gastroenterology identifies the CXCR3 receptor in the ...
... July 24 Tepha, Inc., a developer of,medical ... polymers, announced,today that it has appointed John Hartnett ... Chief Operating Officer. Mr. Hartnett joins Tepha,following an ... he,progressed from field sales, to marketing management, and, ...
... (Becton,Dickinson and Company) (NYSE: BDX ) today reported ... quarter ended June 30, 2008,representing an increase of 14.5 ... rate reflects the favorable impact on all segments,from foreign ... 7 percentage points of the increase in quarterly revenues., ...
... Cancellations and Higher Operating Costs to Affect ... ... 7, 2008, DENVER, July 24 Air Methods Corporation,(Nasdaq: ... an update on second quarter 2008 results., Based on preliminary ...
... alliance of animal,lovers is attacking one of America,s most ... America is struggling with a weight problem. About ... Unfortunately, our pets -- they really,do look like us ... Campaign to End Obesity, a public/private partnership that includes,Harvard ...
... for its module cleanrooms. The feature is a utility panel ... cleanroom appearance. , ... Burnsville, Minn. (PRWEB) July 24, ... systems, announced today that they are now offering a utility panel ...
Cached Medicine News:Health News:Intestinal Gluten Receptor Is Gateway for Celiac Disease 2Health News:Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer 2Health News:BD Announces Results for Third Fiscal Quarter 2Health News:BD Announces Results for Third Fiscal Quarter 3Health News:BD Announces Results for Third Fiscal Quarter 4Health News:BD Announces Results for Third Fiscal Quarter 5Health News:BD Announces Results for Third Fiscal Quarter 6Health News:BD Announces Results for Third Fiscal Quarter 7Health News:BD Announces Results for Third Fiscal Quarter 8Health News:BD Announces Results for Third Fiscal Quarter 9Health News:BD Announces Results for Third Fiscal Quarter 10Health News:BD Announces Results for Third Fiscal Quarter 11Health News:BD Announces Results for Third Fiscal Quarter 12Health News:BD Announces Results for Third Fiscal Quarter 13Health News:BD Announces Results for Third Fiscal Quarter 14Health News:BD Announces Results for Third Fiscal Quarter 15Health News:Air Methods Provides 2nd Quarter Update and Date of Quarterly Conference Call 2Health News:Air Methods Provides 2nd Quarter Update and Date of Quarterly Conference Call 3Health News:Air Methods Provides 2nd Quarter Update and Date of Quarterly Conference Call 4Health News:PetFit Challenge Helps Keep Pets - and Pet Owners - Healthy 2Health News:Gerbig Engineering Announces Availability of Cleanroom Utility Panel 2
Inquire...
... Axiovert 40 inverted ... you have ever expected from a microscope in ... outstanding quality, and functionality. Axiovert 40 has been ... safe as possible thus increasing the efficiency ...
... The Eclipse TE2000S is ... live cell research. It's exclusive ... resolution with high numerical aperatures ... the first inverted microscope to ...
... IX71's modular frame and ... access ports for multiple ... Up to four ports ... to a primary image. ...
Medicine Products: